REHOVOT, ISRAEL--(MARKET WIRE)--Jun 12, 2007 -- Evogene Ltd. announced today that it has completed an Initial Public Offering on the Tel Aviv Stock Exchange (Tel Aviv:EVGN.TA - News). The company sold units consisting of ordinary shares, Series 1 warrants and Series 2 warrants. In total, 3,800,000 shares, 3,900,000 Series 1 warrants and 3,400,000 Series 2 warrants were sold in the offering. In addition, existing shareholders exercised warrants for approximately 2,000,000 ordinary shares, bringing the total new capital raised to approximately $8,000,000.
The Series 1 warrants included in the IPO are exercisable until May 31st, 2009 at a price of 8.45 NIS ($2.02) per share; the Series 2 warrants are exercisable until May 31st, 2011 at a price of NIS 11.05 ($2.64) per share. The full exercise of both series of warrants would approximately generate an additional $16,800,000 of capital.
Ofer Haviv, Evogene President and CEO, stated: “We are very pleased to have completed this IPO which is a significant milestone for the company. The capital raised will enable us to expand our gene discovery efforts, to advance our products towards commercialization, to widen our activities in the field of Biofuels and to be full partners with leading companies worldwide in the development of products arising out of our unique and broadly applicable discovery capability.”
About Evogene
Evogene’s mission is to be a leader in delivering improved plant traits to the agro-biotechnology and biofuels industries through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene’s current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Until its spin-off as a separate company in 2002, Evogene was the agro-biotechnology division of Compugen Ltd. (NasdaqGM:CGEN - News). Evogene’s core in-silico technology, the ATHLETE, is based on Compugen’s proprietary LEADS computational platform.
For additional information, please visit Evogene’s Website at www.evogene.com.
This press release contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “scheduled” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction or state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or state.
Contact:
Contact Information Evogene: Ofer Haviv President and CEO E-mail: Email Contact Tel: +972-8-931-1905
Source: Evogene
